Related by context. All words. (Click for frequent words.) 76 estrogen receptor positive 74 progesterone receptor negative 73 estrogen receptor ER 71 atypical hyperplasia 70 poorer prognosis 69 HER2 negative 69 advanced adenomas 68 hormone receptor negative 68 hormone receptor positive 67 estrogen receptor progesterone receptor 66 pCR 66 premenopausal 66 endometrial cancers 65 BRCA1 mutations 65 Adjuvant chemotherapy 65 BRCA2 mutations 65 lobular carcinoma 65 HER2 positive tumors 65 TT genotype 65 BRCA2 carriers 65 HER2 positive cancers 65 advanced adenoma 64 ductal breast cancer 64 BRCA mutations 64 recurrent VTE 64 KRAS mutations 64 K ras mutations 64 CC genotype 64 HNSCC 64 breast cancer subtypes 63 serous ovarian cancer 63 breast carcinoma 63 BRCA mutation carriers 63 hormone therapy estrogen 63 adjuvant radiotherapy 63 transferrin saturation 63 breast cancers 63 subclinical hyperthyroidism 63 colorectal adenoma 63 PCa 63 atypia 63 invasive lobular carcinoma 63 BRCA2 mutation carriers 63 adenoma 63 endometrial hyperplasia 63 progesterone receptor PR 63 invasive ductal 62 flutamide 62 invasive carcinoma 62 BRCA deficient 62 lobular cancer 62 HER2 positive breast 62 SUVmax 62 preoperative chemotherapy 62 SLNB 62 HER2 receptor 62 #.#ng/ml 62 polyp recurrence 62 lymph node involvement 62 adenocarcinomas 62 colorectal adenomas 62 MGUS 62 situ LCIS 62 metastatic prostate 62 nonmetastatic 62 bladder cancers 62 BRCA1 mutation carriers 62 breast tumors 62 EGFR mutation 62 lymph node metastases 62 AVODART 62 differentiated thyroid 62 salpingo oophorectomy 62 operable breast cancer 62 oophorectomy 62 micrometastases 62 atypical ductal hyperplasia 62 HER2 expression 62 GSTT1 62 tumor histology 62 ABCB1 62 postmenopausal hormones 62 nonmelanoma skin cancers 62 APOE ε4 61 biochemical relapse 61 rs# [002] 61 BRCA gene mutation 61 PSADT 61 prostate cancer CaP 61 squamous histology 61 ovarian carcinoma 61 PCA3 scores 61 HGPIN 61 locoregional recurrence 61 hepatocellular carcinomas 61 neoadjuvant chemotherapy 61 CIN3 61 pre menopausal 61 seminoma 61 colorectal polyp 61 distant metastases 61 benign breast 61 contralateral breast 61 TNF blocker therapy 61 perimenopausal women 61 ErbB2 positive 61 HER2 positive 61 medically inoperable 61 colorectal neoplasia 61 adenomatous polyps 61 breast endometrial 61 pancreatic lung 61 adriamycin 61 invasive ductal carcinoma 61 HER2 overexpression 61 MTHFR 61 invasive ductal breast cancer 61 basal cell nevus syndrome 61 colorectal carcinoma 61 noncarriers 61 CVD mortality 61 multivariate adjustment 61 hormone receptor status 61 mucinous 60 anaplastic 60 premenopausal breast cancer 60 leiomyomas 60 colorectal neoplasms 60 BRCA1 mutation 60 homozygotes 60 epithelial tumors 60 lobular involution 60 MetS 60 overexpress HER2 60 androgen deprivation 60 contralateral breast cancer 60 colorectal tumors 60 p# mutation 60 Papillary 60 invasive ductal carcinomas 60 cisplatin resistant 60 distant metastasis 60 lobular 60 exemestane 60 GISTs 60 uterine ovarian 60 gestational hypertension 60 Carcinoid tumors 60 axillary lymph nodes 60 renal cell carcinomas 60 ERBB2 60 adjuvant therapy 60 thyroglobulin 60 fluvastatin 60 mammographic density 60 ductal cancer 60 invasive lobular 60 epithelial ovarian cancer 60 urine cytology 60 biochemical recurrence 60 invasive breast cancer 60 BRCA2 mutation 60 hypermethylated 60 cervical lesions 60 GSTP1 60 stage IIIb IV 60 beta carotene supplementation 60 adjuvant chemotherapy 60 System IPSS 60 ASCUS 60 apolipoprotein E4 60 recurrent ovarian cancer 60 serum creatinine levels 60 endometriosis ovarian cysts 59 pancreatic adenocarcinoma 59 EGFR mutations 59 neutrophil counts 59 mutated K ras 59 baseline LDH 59 endometrial cancer 59 liver metastasis 59 neoplasias 59 testicular germ cell 59 neoadjuvant therapy 59 chlamydial infection 59 prostate pancreatic 59 NNRTI resistance 59 lumbar spine BMD 59 SHBG levels 59 fetuin 59 BRAF mutations 59 endometrial carcinoma 59 prostate carcinoma 59 BRCA mutation 59 Estrogen receptor 59 cervical carcinoma 59 recurrent ovarian 59 pT2 59 axillary nodes 59 familial pancreatic cancer 59 HER2 + 59 TP# mutations 59 node metastases 59 CLA supplementation 59 dutasteride 59 biopsied breast 59 histologically confirmed 59 squamous cell lung cancer 59 postmenopausal hormone 59 GSTM1 59 lobular breast cancer 59 Basal cell 59 EBRT 59 lymphovascular invasion 59 troponin T 59 tamoxifen Nolvadex ® 59 penetrance 59 prostate cancers 59 seminomas 59 MMSE scores 59 specific antigen PSA 59 MSMB 59 lung adenocarcinoma 59 sarcomatoid 59 inherited mutations 59 APOE e4 59 Hashimoto thyroiditis 59 histological subtype 59 BARD1 59 hematologic toxicity 59 postmenopausal breast cancer 59 lung metastasis 59 mammary tumors 59 UGT#A# * 59 gefitinib Iressa 59 antiandrogens 59 cell carcinomas 59 axillary node 59 SOD2 gene 59 KRAS mutation 59 estrogen progesterone 59 arterial thickening 59 unresectable tumors 59 breast cancer recurrence 59 paricalcitol 59 IGFBP 59 pT3 59 clodronate 59 overt hypothyroidism 59 Colon polyps 59 relapsed ovarian cancer 59 paclitaxel cisplatin 59 Uterine cancer 59 serum PSA 59 confidence interval #.#-#.# 59 creatinine ratio 59 TGFBR1 * 6A 59 parous women 59 intestinal polyps 59 castration resistant 59 thromboembolisms 59 solar keratosis 59 fasting insulin 59 hematopoietic cancers 58 baseline HbA1c 58 Leukemias 58 tibolone 58 Leydig cell 58 kaempferol 58 CD#c 58 LHRH receptor positive 58 eribulin 58 malignant lymphoma 58 neuroblastomas 58 HER2 positive metastatic breast 58 slow metabolizers 58 Prostate specific antigen 58 bilateral oophorectomy 58 GRK5 58 TCF#L# 58 rs# [001] 58 Zolinza 58 B7 H3 58 ductal carcinomas 58 5-FU/LV 58 tamoxifen 58 coinfected 58 highest tertile 58 breast carcinomas 58 grade cervical intraepithelial 58 lactate dehydrogenase LDH 58 relapsed SCLC 58 thyrotropin 58 Adriamycin 58 lobular carcinomas 58 Inhibin B 58 thyroid hormone levels 58 HER2 amplified 58 elevated serum creatinine 58 pancreatic prostate 58 taxane therapy 58 intensive statin therapy 58 phytoestrogen 58 ADPKD 58 prostate colon 58 grade gliomas 58 elevated triglyceride levels 58 adjuvant radiation 58 clinically insignificant 58 colorectal liver metastases 58 sentinel nodes 58 MnSOD 58 adenoma recurrence 58 hamartomas 58 p# mutations 58 sleeve lobectomy 58 stage IIIB 58 Subgroup analysis 58 telomere lengths 58 PTPN# 58 Premenopausal 58 NMIBC 58 premalignant 58 nonseminoma 58 prednisone prednisolone 58 HBeAg negative 58 cerebral infarction 58 hydroxyvitamin D levels 58 metastatic gastric 58 plasma folate 58 lymph node metastasis 58 nonnucleoside reverse transcriptase inhibitors 58 K ras 58 BRCA2 gene mutation 58 sentinel lymph node biopsy 58 vasomotor symptoms 58 endogenous estrogen 58 white matter hyperintensities 58 adenocarcinoma 58 carotid plaques 58 premenopausal women 58 HER2 positivity 58 amnestic mild cognitive impairment 58 spontaneously regress 58 metastatic RCC 58 stage IIIA 58 KIF6 gene 58 postmenopausal 58 KRAS oncogene 58 SHBG 58 sFlt 1 58 Metastatic 58 mycophenolate mofetil 58 lymphomas leukemias 58 nonsmall cell lung cancer 58 recurrent UTI 58 ovarian cancers 58 poor metabolizers 58 narcolepsy cataplexy 58 EGFR mutant 58 colorectal polyps 58 leukaemias 58 endoxifen 58 HER2 amplification 58 catheter angiography 58 nondiabetic patients 58 immunoreactivity 58 histologically 58 elevated LDL cholesterol 58 APOE4 58 colorectal bowel 58 Estrogen Receptor 58 nonalcoholic steatohepatitis NASH 58 DFMO 58 estrogen receptor 58 TRAF1 C5 58 completely resected 58 abnormal mammogram 58 epithelial ovarian 58 polycystic ovary syndrome PCOS 58 intravenous bisphosphonates 58 lymph node removal 58 castrate resistant 58 elevated CRP 58 osteosarcomas 57 medullary thyroid cancer 57 irregular menstrual cycles 57 anti androgen 57 elevated hsCRP 57 axillary node dissection 57 hormone deprivation 57 malignant polyps 57 heterozygotes 57 dysplastic nevi 57 gene polymorphism 57 naturally occurring estrogen 57 extracapsular extension 57 estrone 57 adenomas 57 chemopreventive agent 57 Thal Dex 57 basal cell carcinoma BCC 57 CDKN2A 57 hypertensives 57 Radical prostatectomy 57 K ras mutation 57 tumor recurrence 57 oropharyngeal cancer 57 FOLFOX4 57 endometrial thickness 57 serum selenium 57 KRAS wild 57 liver metastases 57 5 HTTLPR 57 lipid lowering therapy 57 folate deficiency 57 resectable 57 prognostic factor 57 imatinib Gleevec 57 androgen independent 57 serum homocysteine 57 cystatin C 57 daunorubicin 57 Her2/neu 57 recurrent NSCLC 57 prognostic indicator 57 androgen suppression 57 gastric carcinoma 57 GnRH agonists 57 LHRH agonists 57 mRNA expression 57 uterine cancers 57 NAT2 57 rs# [003] 57 HBeAg 57 beta blocker therapy 57 elevated LDH 57 Squamous cell 57 peritoneal carcinomatosis 57 precancer 57 AGTR1 57 Doxil ® 57 dense LDL 57 subclinical hypothyroidism 57 ovarian endometrial 57 Recurrence Score 57 menthol smokers 57 cervical intraepithelial neoplasia 57 dysglycemia 57 tanned indoors 57 nonfatal MI 57 ApoE4 57 selenium intake 57 severe neutropenia 57 inducible nitric oxide synthase 57 pg ml 57 pegylated liposomal doxorubicin 57 Subgroup analyzes 57 cardiovascular mortality 57 ALND 57 squamous cell 57 intima media thickness 57 nondepressed 57 precancerous polyp 57 adenomatous 57 advanced neoplasia 57 precancerous condition 57 Hodgkin lymphoma HL 57 mutated KRAS 57 Soy isoflavones 57 Squamous 57 E selectin 57 virologic failure 57 epirubicin 57 Hurthle cell 57 invasive carcinomas 57 colon tumors 57 serum estradiol 57 uterine tumors 57 bowel polyps 57 non squamous NSCLC 57 oesophageal adenocarcinoma 57 metachronous 57 distal colon cancer 57 nodal metastasis 57 GSTM1 gene 57 small lymphocytic lymphoma 57 SPINK1 57 tumor subtypes 57 carcinoembryonic antigen 57 aminotransferase levels 57 apolipoprotein B 57 APOL1 57 dehydroepiandrosterone sulfate 57 histologic subtype 57 recurrent glioblastoma multiforme 57 PSA velocity 57 ductal carcinoma 57 microbleeds 57 hepatocellular carcinoma HCC 57 glioma tumors 57 VCAM 1 57 lipid abnormalities 57 apolipoprotein E gene 57 serum concentrations 57 oestradiol 57 cyclophosphamide methotrexate 57 CCR5 delta# 57 polycystic ovarian syndrome PCOS 57 hormonally responsive 57 urothelial carcinoma 57 antiandrogen 57 leukemia AML 57 androgen deficiency 57 Ki# 57 haemorrhagic stroke 57 metastatic lung cancer 57 lipid lowering medications 57 pheochromocytomas 57 sorafenib Nexavar 57 metastatic malignant 57 ischemic lesions 57 curable cancers 57 infarcts 57 endocrine therapies 57 papillary 57 hsCRP levels 57 thyroid nodules 57 rheumatoid factor 57 Paraplatin ® 57 gamma tocopherol 57 recurrent venous thromboembolism 57 Menopausal hormone therapy 57 neoadjuvant 57 bladder carcinoma 57 CYP#B# 57 esophageal squamous cell carcinoma 57 interferon IFN 57 shorter telomere length 57 polypoid 57 dasatinib 57 EGFR mutation positive 57 Anaplastic 57 HER-2/neu 57 Ovary removal 57 pre cancerous polyps 57 colon polyps 56 CYT# potent vascular disrupting 56 gestational diabetes mellitus 56 metastatic HER2 negative 56 PCNSL 56 CP CPPS 56 develop premenopausal breast 56 serum urate levels 56 Multivariate analyzes 56 chlorambucil 56 nonpregnant women 56 ε4 56 elevated depressive symptoms 56 neurodevelopmental outcome 56 estrogen receptor beta 56 alkylating agents 56 ductal lobular 56 DQB1 * 56 premalignant lesions 56 gefitinib 56 fibroadenomas 56 precursor lesions 56 Basal Cell 56 nmol liter 56 undergo prostate biopsy 56 extrapyramidal symptoms 56 hereditary breast cancer 56 IDH1 mutation 56 promoter methylation 56 hormonal therapies 56 antiphospholipid antibodies 56 sarcosine 56 BRCA gene mutations 56 mutant KRAS 56 basal cell cancers 56 radical nephrectomy 56 neoadjuvant treatment 56 nonobese 56 postoperative chemotherapy 56 preoperative PSA 56 curative resection 56 abnormal Pap test 56 nonmelanoma 56 antiestrogen 56 CIN2 + 56 PLX STROKE targeting 56 Epidemiologic studies 56 Acute myeloid leukemia 56 breast tenderness 56 EpCAM expression 56 rs# [004] 56 urothelial bladder cancer 56 circulating endothelial cells 56 GBA mutations 56 untreated mice 56 lymphocytosis 56 deCODE BreastCancer TM 56 abnormal mammograms 56 malondialdehyde 56 univariate analysis 56 erlotinib 56 lung carcinomas 56 nontasters 56 aminotransferases 56 denser breasts 56 DLBCL 56 skeletal metastases 56 prostate ovarian 56 metastatic lesions 56 oral clodronate 56 squamous cell skin 56 transaminase levels 56 overt hepatic encephalopathy HE 56 colorectal gastric 56 colorectal cancer CRC 56 interleukin IL -6 56 Akt activation 56 Adenocarcinoma 56 anastrozole 56 CYP#D# genotype 56 elevated ALT 56 Endometrial 56 plasma lipid 56 abnormal cytology 56 T1c 56 thyrotoxicosis 56 shorter telomeres 56 cranial irradiation 56 P = .# 56 lupus anticoagulant 56 iniparib 56 coronary artery calcification 56 GnRH agonist 56 5alpha reductase 56 folate intake 56 ventricular tachyarrhythmia 56 albumin excretion rate 56 estrogen progestin therapy 56 acute myelogenous leukemia AML 56 serum folate 56 lipid lowering drugs 56 folic acid folate 56 detecting precancerous 56 thyrotropin levels 56 colorectal pancreatic 56 TEAEs 56 enzyme elevations 56 Platinol 56 neurocognitive function 56 Combination therapy 56 ovarian lung 56 deCODE BreastCancer 56 mammographically 56 TMPRSS2 ERG 56 anthracycline taxane 56 erlotinib Tarceva 56 moderate renal impairment 56 neoplasia 56 CI #.#-#.# [002] 56 lactate dehydrogenase 56 aromatase 56 undergone hysterectomy 56 colorectal carcinomas 56 hypogonadal 56 BRAF mutation 56 CD# + [001] 56 osteopenic 56 SNP rs# [001] 56 androgen ablation 56 malignant lesions 56 FDG uptake 56 testicular cancers 56 neoplasms 56 plasma homocysteine levels 56 fibroids endometriosis 56 lignan intake 56 IgA deficiency 56 HbA 1c levels 56 bronchopulmonary dysplasia 56 Ovarian cysts 56 undergone radical prostatectomy 56 mutated BRCA1 56 perioperative complications 56 isoprostane 56 bezafibrate 56 aromatase inhibitors AIs 56 gastric cancers 56 C#Y 56 protein excretion 56 overexpress 56 serum calcium levels 56 haematologic 56 HBeAg positive 56 axillary dissection 56 Hilakivi Clarke 56 corticosteroid therapy 56 distal colon 56 fallopian tube carcinoma 56 bowel cancers 56 sulphonylureas 56 missense mutations 56 TMEM#B 56 metastatic renal cell carcinoma 56 drank colas 56 BRAF V#E 56 cisplatin chemotherapy 56 nonischemic 56 LRP5 56 serum prostate 56 minimally symptomatic 56 hormonal therapy 56 cryptogenic 56 tHcy 56 basal cell skin 56 Kaplan Meier analysis 56 HBsAg 56 acrylamide intake 56 PKCi 56 sentinel node biopsy 56 tirofiban 56 relapsed MM 56 lung cancer NSCLC 56 BMPR2 56 CIN3 + 56 chronic lymphocytic leukemia CLL 56 univariate analyzes 56 alpha tocopherol 56 nodal metastases 56 hormones progesterone 56 leiomyoma 56 recurrent metastatic 56 neoplasm 56 acute leukemias 56 triglyceride concentrations 56 TOP2A 56 Postmenopausal Women 56 Paraplatin ® carboplatin 56 cTnT 56 pulmonary metastases 56 serum IGF 56 allogeneic stem cell 56 SGPT 56 KRAS status 56 anti inflammatory cytokine 56 IFN gamma 56 mycosis fungoides 56 alanine aminotransferase 56 adiponectin concentrations 56 nonfasting triglyceride levels 56 prolonged QT interval 56 diabetes mellitus DM 56 serum leptin 56 prostate cancer PCa 56 mammary cancers 56 Clusterin 56 ovarian tumors 56 alanine aminotransferase ALT 56 CagA 56 leukopenia 56 receiving VICTRELIS 56 RET PTC rearrangements 56 hyperplasia 56 ER CHOP 56 vWD 56 μmol L 56 virologic response 56 Folate deficiency 56 tricyclic antidepressants 56 highest quintile 56 prognostically 55 gene amplification 55 FLT3 ITD 55 chemotherapy cisplatin 55 primary ovarian insufficiency 55 antibody titer 55 taxane chemotherapy 55 Pancreatic neuroendocrine tumors 55 zoledronic acid 55 inhibin B 55 multivariate Cox 55 ovarian cancer 55 precancerous tumors 55 testosterone supplementation 55 benign lesions 55 TOP2A gene 55 atopic asthma 55 amisulpride 55 CaP 55 LV dysfunction 55 AML MDS 55 STAT4 55 subclinical atherosclerosis 55 serum triglycerides 55 EGFR inhibitors 55 estrogen receptors 55 squamous cell carcinoma SCC 55 Premenopausal women 55 resistant hormone refractory 55 serum uric acid 55 sulfasalazine 55 p# activation 55 nondiabetic 55 heterozygous 55 coronary calcification 55 pelvic lymphadenectomy 55 oral squamous cell 55 venlafaxine Effexor 55 fasting triglyceride levels 55 CYP#D# 55 histologic subtypes 55 complete cytogenetic response 55 TNFalpha 55 hereditary hemochromatosis 55 HBeAg seroconversion 55 ginkgo biloba extract 55 leucopenia 55 nelfinavir 55 d4T 55 Adjuvant Chemotherapy 55 metastatic bladder 55 ovarian uterine 55 lung metastases 55 Heterozygous 55 prophylactic mastectomy 55 histone deacetylases 55 cabazitaxel 55 estrogen metabolites 55 trastuzumab 55 axillary lymph node dissection 55 isoflavones 55 HIV uninfected 55 IL#B 55 Postmenopausal 55 TIMP 1 55 nonmelanoma skin cancer 55 normotensive 55 carcinomas 55 testicular tumors 55 metastatic prostate cancer 55 intestinal metaplasia 55 debulking surgery 55 androgen dependent 55 standard chemotherapy regimens 55 papillary renal cell carcinoma 55 Exemestane 55 hyperplastic 55 spontaneous preterm birth 55 F FDG PET 55 MS relapses 55 phytoestrogens 55 del 5q MDS 55 ductal 55 Peritoneal mesothelioma 55 benign nodules 55 fluorouracil 55 Uterine fibroids 55 Nilotinib 55 CALHM1 55 esophageal adenocarcinoma 55 activin 55 nonresponders 55 endocrine therapy 55 c MYC 55 XELOX 55 hyperplastic polyps 55 Wwox 55 SHANK3 55 nondrinkers 55 T1DM 55 urinary bladder cancer 55 monoinfected patients 55 CR nPR 55 serum phosphate 55 genital tract infections 55 HER2 positive breast cancer 55 #ng/ml 55 ApoE4 gene 55 Adenomas 55 typical antipsychotics 55 radiosensitive 55 IV bisphosphonates 55 adjunctive ABILIFY 55 gastric adenocarcinoma 55 chromosomal rearrangement 55 malignant pleural mesothelioma 55 BRAF gene mutations 55 K ras gene 55 calcified plaques 55 carbohydrate intolerance 55 proximal colon 55 calcitriol 55 citalopram Celexa 55 chemoresistant 55 Anthracycline 55 LDL cholesterol concentrations 55 carcinoid 55 locoregional 55 pheochromocytoma 55 hypercholesterolemic patients 55 hereditary predisposition 55 ddI 55 cancerous enlargement 55 serum folate concentrations 55 postnatally 55 TCF#L# gene 55 ALT elevation 55 Faslodex 55 nutlin 3a 55 SE alleles 55 DRB1 * 55 multivariable adjusted 55 APOE gene 55 tertile 55 calcium oxalate stones 55 faulty BRCA2 gene 55 tumors 55 serum albumin 55 histologies 55 surgically resectable 55 sex hormones estrogen 55 nucleoside analogue 55 hydroxymethyl coenzyme 55 Heavy menstrual bleeding 55 ovarian function 55 hyperplasia BPH 55 lamotrigine 55 macroalbuminuria 55 diagnostic biomarker 55 Platinol ® cisplatin 55 thiazides 55 basal cell carcinomas 55 Folfox 55 K#R [002] 55 gallstone disease 55 Stent thrombosis 55 serum urate 55 antigen PSA 55 interleukin IL -# 55 BRCA carriers 55 HPV# 55 albumin excretion 55 severe periodontitis 55 astrocytomas 55 virological response 55 #F FDG 55 GBM tumors 55 nondiabetics 55 leukemia multiple myeloma 55 CK MB 55 antiestrogen therapy 55 gemcitabine Gemzar 55 heavily pretreated 55 oligodendroglioma 55 carotid stenosis 55 germline mutations 55 prostate tumor 55 Her2 positive 55 bicalutamide 55 homozygous familial hypercholesterolemia 55 serum BDNF 55 Lenalidomide 55 receptor inhibitor 55 mammographic breast density 55 III EGFRvIII 55 heavily pretreated patients 55 follicle stimulating hormone FSH 55 brain lesions 55 imatinib resistant 55 CANCIDAS 55 urate levels 55 malignant prostate 55 affective psychosis 55 serum testosterone 55 amenorrhea 55 periprocedural MI 55 endometrioid 55 umol L 55 Erlotinib 55 aromatase inhibitor 55 normal karyotype 55 NPH insulin 55 LY# [003] 55 anal lesions 55 Osteopenia 55 dapagliflozin plus 55 % CI #.#-#.# [006] 55 T2DM 55 sitosterol 55 epithelioid 55 underwent prostatectomy 55 airway hyper responsiveness 55 HDL2 55 anastrazole